


October  
**25-27**  
2018

Hotel Garden  
Siena

PROGRAM



# II THINK TANK

## A VISION OF I-O THE SIENA CONSENSUS 2018

Promoted by the NIBIT Foundation in collaboration with the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council



**PARKER  
INSTITUTE**  
for CANCER IMMUNOTHERAPY

**WIC**  
World Immunotherapy Council



# A VISION OF I-O

Thursday **October**  
**25<sup>th</sup>**  
**2018**

18:00 - 20:00

# **Tuning-up for the THINK TANK: the world-wide I-O voice**

## **My I-O story**

Stefanie Joho (Philadelphia, USA)

## **NIBIT Foundation**

Michele Maio (Siena, Italy)

## **Parker Institute for Cancer Immunotherapy**

Ramy Ibrahim (San Francisco, USA)

## **World Immunotherapy Council**

Bernie Fox (Portland, USA)

## **The Bloomberg Perspective in I-O**

Asthika Goonewardene (New York City, USA)

## **My I-O story**

Andrea Bifarini (Terni, Italy)

20:30

**Wine & cheese**



Friday  
**October  
26<sup>th</sup>  
2018**

08:45 - 09:00 **Welcome addresses**

Michele Maio (Siena, Italy), Bernie Fox (Portland, USA)  
and Ramy Ibrahim (San Francisco, USA)

## **SESSION 1 | Lung cancer: finding the path ahead**

**Chairs: Luis Paz-Ares (Madrid, Spain), Fouad Namouni (Lawrenceville, USA)  
and Giovanni Melillo (Washington D.C., USA)**

09:00  **State of the art** - Andrea Ardizzone (Bologna, Italy)

09:20  **Current and perspective challenges**  
Discussant: Luis Paz-Ares (Madrid, Spain)

 **Critical insights**

09:50 **The predictive role of TMB** - Massimo Barberis (Milan, Italy)

10:05 **Combining immuno- and chemo-therapy** - Giovanni Melillo (Washington D.C., USA)

10:20 **Young investigator idea - Rationale for cancer vaccines design guided  
by antibody survey** - Tyler W. Hulett (Portland, USA)

10:30 **Comprehensive Faculty consensus**

11:00 - 11:30 *Coffee break*

## **SESSION 2 | The melanoma "immune" lesson: past, present, and future**

**Chairs: Alexander M.M. Eggermont (Paris, France), Martin Janek (Bratislava, Slovak Republic)  
and Pier Giorgio Natali (Rome, Italy)**

11:30  **State of the art** - Anna Maria Di Giacomo (Siena, Italy)

11:50  **Current and perspective challenges**  
Discussant: Alexander M.M. Eggermont (Paris, France)

 **Critical insights**

12:20 **Microbiota** - Maria Rescigno (Milan, Italy)

12:35 **Immune contexture** - Wolf Hervé Fridman (Paris, France)

12:50 **Young investigator idea - Tbc**

13:00 **Comprehensive Faculty consensus**

13:30 - 14:30 *Lunch break*

## SESSION 3 | Epigenetic immunomodulation: a win-win approach?

**Chairs: Soldano Ferrone (Boston, USA), Mohammad Azab (Pleasanton, USA) and Elisabetta Ferretti (Rome, Italy)**

14:30  **State of the art** - Michele Maio (Siena, Italy)

14:50  **Current and perspective challenges**  
Discussant: Soldano Ferrone (Boston, USA)

### **Critical insights**

15:20 **Epigenetics in the melanoma clinic** - Alessia Covre (Siena, Italy)

15:35 **Genetic basis of tumor antigenicity, recognition and resistance** - Drew Pardoll (Baltimore, USA)

15:50 **Young investigator idea - NK epigenetics** - Chiara Vitale (Genoa, Italy)


16:00 **Comprehensive Faculty consensus**

16:30 - 17:00 *Tea break*

## SESSION 4 | Cancer vaccines: ready again for the prime time?

**Chairs: Bernie Fox (Portland, USA), Roberto Camerini (Bologna, Italy) and Samir Khleif (Augusta, USA)**

17:00  **State of the art** - Pier Luigi Lollini (Bologna, Italy)

17:20  **Current and perspective challenges**  
Discussant: Bernie Fox (Portland, USA)


### **Critical insights**

17:50 **Personalized vs shared** - Mahesh Yadav (South San Francisco, USA)

18:05 **Boosting T cell response to vaccines** - Samir Khleif (Augusta, USA)

18:20 **Young investigator idea - Neoantigens released by Salmonella-infected tumor cells as a novel vaccine platform** - Alessia Melacarne (Milan, Italy)

18:30 **Comprehensive Faculty consensus**



Saturday  
**October  
27<sup>th</sup>  
2018**

## **SESSION 5 | Big data and data deconvolution**

**Chairs: Nikesh Kotecha (San Francisco, USA), Olivier Provendier (Paris, France)  
and Dominik Ruettinger (Munich, Germany)**

08:30 **High level landscape/overview** - Chairs

08:40  **State of the art: I-0 computational science** - Zlatko Trajanosky (Innsbruck, Austria)

### **Critical insights**

09:00 **Integrative analyses** - Nicholas L. Bayless (San Francisco, USA)

09:15 **Deep dive talk on analytics for a new technology** - Petter Brodin (Stockholm, Sweden)

09:30 **Young investigator idea - Data deconvolution** - Francesca Finotello  
(Innsbruck, Austria)

09:40 **Current and perspective challenges/Comprehensive Faculty Consensus**  
Discussant: Nikesh Kotecha (San Francisco, USA)

10:30 - 11:00 *Coffee break*

## **SESSION 6 | Learning from existing data: IDO, OX40, HDACi...**

**Chairs: Ramy Ibrahim (San Francisco, USA), Patrick Garcia (Aubonne, Switzerland),  
and Michael Lahn (Geneve, Switzerland)**

11:00 **State of the art** - Kevin Heller (Washington D.C., USA)

11:20  **Current and perspective challenges**

 Discussant: Ramy Ibrahim (San Francisco, USA)

### **Critical insights**

11:50  **Are we neglecting the biology behind?** - Andrea Anichini (Milan, Italy)

12:05 **Oncolytic virotherapy: from mono to combo** - Graeme Norman V. Hacking  
(Thousand Oaks, USA)

12:20 **Young investigator idea - Cancer testis antigen-based  
immune cell vaccines** - Patrizia Tunici (Siena, Italy)

12:30 **Comprehensive Faculty consensus**

## **SESSION 7 | The III Siena I-O Think Tank 2019**

**Chairs: Michele Maio (Siena, Italy), Ramy Ibrahim (San Francisco, USA) and Bernie Fox (Portland, USA)**


13:00      **Shall we refine the formula? Topics for next year?**  
**Any other ideas and suggestion? - All**

14:00      *Lunch*



**THE III THINK TANK "A VISION OF I-O: THE SIENA CONSENSUS 2019"**  
OCTOBER 3-5, 2019  
HOTEL GARDEN  
SIENA

# **SEE YOU NEXT YEAR!**



## SCIENTIFIC COMMITTEE

**Michele Maio** - Center for Immuno-Oncology, Siena (Italy)

**Ramy Ibrahim** - Parker Institute for Cancer Immunotherapy, San Francisco (USA)

**Bernie Fox** - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland (USA)

**George Coukos** - University of Lausanne, Lausanne (Switzerland)

**Jedd D. Wolchok** - Memorial Sloan Kettering Cancer Center, New York, USA

**Axel Hoos** - GlaxoSmithKline, Philadelphia (USA)

**Andrea Anichini** - Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)

**Wolf Hervé Fridman** - Centre de Recherche des Cordeliers, Paris (France)

## FACULTY

**Andrea Anichini** - Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)

**Andrea Ardizzoni** - Alma Mater Studiorum – University of Bologna, Bologna (Italy)

**Mohammad Azab** - Astex Pharmaceuticals, Pleasanton (USA)

**Massimo Barberis** - Istituto Europeo di Oncologia, Milan (Italy)

**Nicholas L. Bayless** - Parker Institute for Cancer Immunotherapy, San Francisco (USA)

**Andrea Bifarini** – Terni (Italy)

**Petter Brodin** - Karolinska Institutet, Stockholm (Sweden)

**Roberto Camerini** - Alfasigma, Bologna (Italy)

**Alessia Covre** - Center for Immuno-Oncology, Siena, (Italy)

**Anna Maria Di Giacomo** - Center for Immuno-Oncology, Siena (Italy)

**Alexander M.M. Eggermont** – Goustave Roussy, Paris-Sud University, Paris (France)

**Elisabetta Ferretti** - Sapienza University, Rome (Italy)

**Soldano Ferrone** - Harvard Medical School, Boston (USA)

**Francesca Finotello** - Medical University of Innsbruck, Innsbruck (Austria)

**Bernie Fox** - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland (USA)



**Wolf Hervé Fridman** - Centre de Recherche des Cordeliers, Paris (France)  
**Patrick Garcia** - Merck KGaA, Aubonne, Canton Vaud (Switzerland)  
**Graeme Norman V. Hacking** - Amgen, Thousand Oaks (USA)  
**Kevin Heller** - NextCure, Washington D.C. (USA)  
**Tyler W. Hulett** - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland (USA)  
**Ramy Ibrahim** - Parker Institute for Cancer Immunotherapy, San Francisco (USA)  
**Martin Janek** - Merck, Bratislava (Slovak Republic)  
**Stefanie Joho** - Philadelphia (USA)  
**Samir Khleif** - Georgia Cancer Center, Augusta (USA)  
**Nikesh Kotecha**, - Parker Institute for Cancer Immunotherapy, San Francisco (USA)  
**Michael Lahn** - Incyte Biosciences International, Geneva (Switzerland)  
**Pier Luigi Lollini** - Alma Mater Studiorum – University of Bologna, Bologna (Italy)  
**Michele Maio** - Center for Immuno-Oncology, Siena, (Italy)  
**Alessia Melacarne** - Humanitas University, Milan (Italy)  
**Giovanni Melillo** - AstraZeneca, Washington D.C. (USA)  
**Fouad Namouni** - Bristol-Myers Squibb, Lawrenceville, (USA)  
**Pier Giorgio Natali** - NIBIT Foundation ONLUS, Siena (Italy)  
**Asthika Goonewardene** - Bloomberg Intelligence, New York (USA)  
**Drew Pardoll** - Johns Hopkins University School of Medicine, Baltimore (USA)  
**Luis Paz-Ares** - Hospital Universitario 12 de Octubre, Madrid (Spain)  
**Olivier Provendier** - Pierre Fabre Médicament, Paris (France)  
**Maria Rescigno** - Humanitas Research Hospital, Milan, (Italy)  
**Dominik Ruettinger** - Roche, Munich (Germany)  
**Zlatko Trajanoski** - Medical University of Innsbruck, Innsbruck (Austria)  
**Patrizia Tunicci** - Center for Immuno-Oncology, Siena (Italy)  
**Chiara Vitale** - University of Genoa, Genoa, (Italy)  
**Mahesh Yadav** - Genentech, South San Francisco (USA)

## INVITEES FACULTY

**Gregorio Aversa** - Abimmune Technologies, Vancouver (Canada)  
**Marc Ballas** - GlaxoSmithKline, Washington D.C. (USA)  
**Catherine Sautès-Fridman** - Centre de Recherche des Cordeliers, Paris (France)  
**Michael Imperiale** - NEKTAR, San Francisco (USA)  
**Daniela Massi** – Università degli Studi, Florence (Italy)  
**Paola Nisticò** - Regina Elena, National Institute for Cancer Treatment and Research, Rome (Italy)  
**Cosimo Paga** - Bristol-Myers Squibb, Rome (Italy)  
**Giuseppe Palmieri** - Institute of Biomolecular Chemistry-CNR, Sassari (Italy)  
**Ulrich Pfeffer** - San Martino Hospital, National Institute for Cancer Research, Genoa (Italy)  
**Barbara Seliger** - Martin Luther Universität Halle-Wittenberg, Halle (Germany)

## PROMOTED BY

---



## PLATINUM SPONSOR



Bristol-Myers Squibb

## GOLD SPONSOR



## SILVER SPONSORS



## BRONZE SPONSORS




---

## SUPPORTED BY



## ENDORSERS

---



# Meeting Venue

Hotel Garden  
Via Custoza, 2  
Siena, Italy

## Scientific Secretariat



### NIBIT Foundation ONLUS

Phone: +39 3490582533

Fax +39 0577 586303

segreteria@fondazionenibit.org

www.fondazionenibit.org

www.thinktank-nibitfoundation.org

## Organizing Secretariat



### McCann Complete Medical

Divisione di VyvaMed Srl

Via Spadolini, 7 - Centro Leoni, Palazzo B - 20141 Milano

Phone: +39 02 5416951 - Fax +39 02 54169554